Investigational New Drugs

, Volume 24, Issue 5, pp 423–427 | Cite as

Phase 1 trial of Anvirzel™ in patients with refractory solid tumors

  • Tarek Mekhail
  • Hanspreet Kaur
  • Ram Ganapathi
  • G. Thomas Budd
  • Paul Elson
  • Ronald M. Bukowski
Phase I Studies

Summary

AnvirzelTM is an aqueous extract of the plant Nerium oleander which has been utilized to treat patients with advanced malignancies. The current study reports a phase 1 trial to determine the maximum tolerated dose (MTD) and safety of AnvirzelTM in patients with advanced, refractory solid tumors. Patients were randomized to receive this agent by intramuscular injection at doses of 0.1, 0.2, 0.4 ml/m2/day with subsequent patients receiving 0.8 or 1.2 ml/m2/day sequentially. Eighteen patients were enrolled and completed at least one treatment cycle of three weeks. Most patients developed mild injection site pain (78%). Other toxicities included fatigue, nausea, and dyspnea. Traditional dose limiting toxicity was not seen, but the MTD was defined by injection volume as 0.8 ml/m2/day. No objective anti-tumor responses were seen. Anvirzel™ can be safely administered at doses up to 1.2 ml/m2/day, with the amount administered intramuscularly limited by volume. The recommended phase II dose level is 0.8 ml/m2/day.

Keywords

Advanced malignancy Oleandrin Cardiac glycosides Antineoplastic activity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Langford SD, Boor PJ (1996) Oleander toxicity: An examination of human and animal toxic exposures. Toxicology 109(1):1–13PubMedCrossRefGoogle Scholar
  2. 2.
    Manna SK, Sah NK, Newman R, Cismerps A, Aggarwal BB (2000) Oleandrin suppresses activation of nuclear transcription of factor-B, activator protein-2 and c-Jun NH2-terminal kinase. Cancer Res 60:3838–3847PubMedGoogle Scholar
  3. 3.
    Abe F, Yamaguchi T (1978) Digitoxigenin oleandroside and 5α-Adynerin in the leaves of Nerium odorum. Chem Pharm Bull 26:3023–3027Google Scholar
  4. 4.
    Abe F, Yamaguchi T (1979) Oleasides-novel cardenolies with an unusual framework on Nerium. Chem Pharm Bull 27:1604–1610PubMedGoogle Scholar
  5. 5.
    Wang X, Plomley JB, Newman RA, Cisneros A (2000) LC(MS(MS analyses of an oleander extract for cancer treatment. Anal Chem 72(15):3547–3552PubMedCrossRefGoogle Scholar
  6. 6.
    Smith JA, Madden T, Vijjeswarapu M, Newman RA (2001) Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU 145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 62(4):469–472PubMedCrossRefGoogle Scholar
  7. 7.
    Jortani SA, Helm RA, Valdes R (1996) Inhibition of Na,K-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem 42:1654–1658PubMedGoogle Scholar
  8. 8.
    Pathak S, Multani AS, Narayan S, Kumar V, Newman RA (2000) Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer Drugs 11(6):455–463PubMedCrossRefGoogle Scholar
  9. 9.
    McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA (2000) Cardiac glycosides stimulate Ca increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 60(14):3807–3812PubMedGoogle Scholar
  10. 10.
    WHO (1979) Handbook for Reporting Results for Cancer Therapy. WHO, GenevaGoogle Scholar
  11. 11.
    Gupta A, Joshi P, Jortani SA, Valdes R Jr, Thorkelsson T, Verjee Z, Shemie S (1997) A case of nondigitalis cardiac glycoside toxicity. The Drug Monit 19(6):711–714CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  • Tarek Mekhail
    • 1
  • Hanspreet Kaur
    • 2
  • Ram Ganapathi
    • 1
  • G. Thomas Budd
    • 1
  • Paul Elson
    • 1
  • Ronald M. Bukowski
    • 1
  1. 1.Taussig Cancer Center, Cleveland Clinic Foundation, ClevelandCase Comprehensive Cancer CenterCleveland
  2. 2.Ireland Cancer CenterUniversity Hospitals, Case Comprehensive Cancer CenterIreland

Personalised recommendations